Efficacy and Safety of Osimertinib in a Hemodialysis Patient With Advanced Non-Small Cell Lung Cancer.
Department of Internal Medicine, Koseiren Sanjo General Hospital, Sanjo, Japan.
Yoichi
Y
Iwafuchi
Department of Internal Medicine, Koseiren Sanjo General Hospital, Sanjo, Japan.
Isao
I
Saito
Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Ichiei
I
Narita
D000178:Acrylamides; D000814:Aniline Compounds; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006435:Renal Dialysis; D016896:Treatment Outcome; D007211:Indoles; D011743:Pyrimidines
D000178:Acrylamides; D000814:Aniline Compounds; D000970:Antineoplastic Agents; D010879:Piperazines; D047428:Protein Kinase Inhibitors; C000596361:osimertinib; D007211:Indoles; D011743:Pyrimidines